Navigation Links
Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles.
Date:11/18/2009

SAN FRANCISCO, Nov. 18 /PRNewswire/ -- Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection. The study's primary endpoint was non-inferiority of once-daily valomaciclovir compared to thrice-daily valacyclovir in terms of time to complete crusting of the shingles rash. The double-blinded study enrolled 373 patients, randomized into 3 arms: 1 gram of once-daily EPB-348, 2 grams of once-daily EPB-348, thrice-daily valacyclovir (1 gram, three times per day). Eighteen patients also received 3 grams of once-daily EPB-348.

Once-daily EPB-348 at two grams met its primary endpoint of non-inferiority to valacyclovir. Valomaciclovir (EPB-348) was also non-inferior to valacyclovir in the secondary endpoints of time to complete pain resolution, time to rash resolution and time to cessation of new lesion formation. The highest dose of valomaciclovir (3 grams once daily) demonstrated superiority to valacyclovir with regards to the primary endpoint (p-value < 0.007).

Dose-dependent trends to improved pain resolution in the subset of treated patients who were over 50 years old and trends to faster resolution of severe pain in patients of all ages were seen in the higher dose EPB-348 treatment arms when compared to valacyclovir. All doses of EPB-348 showed improvement over valacyclovir for patients presenting for first treatment towards the end of the 72 hour treatment window. Currently-approved shingles treatments are effective only within the first 72 hours of rash appearance.

"These Phase 2 data indicate that once-daily valomaciclovir could be more convenient than three times daily valacyclovir for the treatment of herpes zoster, and it is equally safe. Moreover, the 3 gram dose of valomaciclovir was superior to valacyclovir in terms of clinical efficacy. Therefore, Phase 3 studies with larger numbers of patients are clea
'/>"/>

SOURCE Epiphany Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
2. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
3. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... The global Bioinformatics ... sectors, products & services and application. And the rising ... increasing demand of advanced drugs for the diagnosis ... growth for bioinformatics market. The implementation of information ... as bioinformatics. Decreasing cost of DNA sequencing, continuous ...
(Date:9/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r8v22b/regulatory ) has announced the ... (London, UK - September 24-25, 2015)" conference to ... provides an introduction to Pharmaceutical Regulatory Affairs and the ... for those working in a support staff role. ... regulatory procedures required to register products in ...
(Date:9/1/2015)... , September 1, 2015 - ... GARFIELD-AF R egistry data presented at ... on the evolution of manag ... -   The first-ever two-year outcomes from ... ESC Congress 2015 expose that all-cause death was the most frequent major event ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
(Date:9/1/2015)... ... September 01, 2015 , ... ... a top-five hospital by U.S. News & World Report, to provide breaking news ... , Editorial and marketing groups within OncLive, which provides oncologists resources and information?they ...
(Date:9/1/2015)... ... September 01, 2015 , ... The Jerry Segal Classic to benefit ... and Green Valley Country Club in Lafayette Hill, PA. Over the past 26 years, ... million for programs and services designed to support patients and their families during their ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... With former ... Engineering and Math) disciplines since its inception more than 35 years ago. A pilot ... students and their teachers - and, not just those intent on pursuing careers in ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... the release of version 5.2 of the FirstSpirit Content Management System with new ... With the new version of FirstSpirit, companies will be well on their way ...
(Date:9/1/2015)... ... September 01, 2015 , ... Zecurion, a leading developer of data loss prevention ... of endpoint DLP developed specifically for Mac OS. , In June 2015, the company ... and information security professionals had participated. The beta test done by the developer community ...
Breaking Medicine News(10 mins):Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Zecurion Announces Endpoint Security for Mac 2
... the President,s Cancer Panel, investigators at the U.S. EPA,s Office of ... EPA Administrator to use regulatory authorities authorized by Congress to protect ... ... Atlanta, GA (PRWEB) January 22, 2009 -- A growing ...
... Although primary prostate surgery or radiotherapy is successful in many ... of the disease, which is most often first detected by ... affects 30% to 40% of patients after surgery. One risk ... prostate after surgery, will affect about a third of men. ...
... University HealthSystem,Consortium (UHC) today announced that after a ... satisfaction measurement services to Avatar,International and Press Ganey ... agreement with options to extend. The agreements are ... Under the agreements, Avatar and Press ...
... Veteran to Drive International Retail Expansion, With Near Term ... WrinkleFree Brand Line ExtensionIRVINE, Calif., Jan. 21 ... of medically developed and efficacy-based skin and beauty care ... locations throughout the U.S., announced today that it has ...
... HARRISBURG, Pa., Jan. 21 The following statement ... Vice President, Capital BlueCross:"Capital BlueCross has consistently said ... this or any other merger. But we have ... hard before approving this proposed merger without conditions, ...
... Omnicell, Inc. (Nasdaq: OMCL ), a leading provider of ... to discuss the Company,s fourth quarter 2008 financial results. , ... webcast, ... Randall Lipps, chairman, president and chief executive officer, ...
Cached Medicine News:Health News:Scientists and Investigators Cite Need for Radon Regulation to Prevent Lung Cancer- Call Current EPA Efforts Ineffective 2Health News:Scientists and Investigators Cite Need for Radon Regulation to Prevent Lung Cancer- Call Current EPA Efforts Ineffective 3Health News:Scientists and Investigators Cite Need for Radon Regulation to Prevent Lung Cancer- Call Current EPA Efforts Ineffective 4Health News:Treatments after prostate surgery reported in the Journal of Urology 2Health News:Treatments after prostate surgery reported in the Journal of Urology 3Health News:University HealthSystem Consortium Announces Dual Award for Patient Satisfaction Measurement Services 2Health News:University Medical Pharmaceuticals Appoints Tom Roche as Senior Vice President, Global Sales and Marketing 2Health News:University Medical Pharmaceuticals Appoints Tom Roche as Senior Vice President, Global Sales and Marketing 3Health News:Capital Blue Cross Issues Statement on Withdrawal of Merger 2Health News:Omnicell to Release Fourth Quarter 2008 Earnings Results on January 29 2
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: